CAP@YourService – Residents Issue – Fall 2009
Posted November 17, 2009
The College of American Pathologists (CAP) Personalized Health Care Committee is developing a series of free one-hour informational Web teleconferences to raise the visibility of personalized health care (PHC) within the College as part of the CAP’s Transformation Program.
Join us on Wednesday, December 2, 1:00–2:00 PM CST, to hear Samuel K. Caughron, MD, FCAP, Residents Forum chair from 2006–2007 and now a third-year CAP Fellow, speak on “Personalized Pathology: PHC in the General Pathology Practice.”
Dr. Caughron will present an overview on how PHC intersects with the everyday practice of pathology, including routine surgical pathology. The Web teleconference will address questions such as:
- How can a group position itself to share in the growth of molecular diagnostics?
- What elements of PHC are of interest to and practical in a rural pathology practice?
- What tests should be considered?
- What is the business model?
- How can a practice get needed expertise in molecular diagnostics?
- How much time should be allocated?
- What are the incentives and the barriers?
Specific tests that will be discussed include KRAS for colon cancer, BRAF for thyroid cancer, CYP2D6 genotyping for tamoxifen resistance, and CYP2C19 for clopidogrel resistance.
Dr. Caughron practiced pathology in a rural Montana practice for two years where he set up a molecular pathology laboratory. He is currently with MAWD Pathology Group in Kansas City, Missouri.
Other scheduled PHC Web teleconferences in the series include:
Much discussion on Capitol Hill is taking place about the new coordinated care model. This dialog raises implications for pathologists. The “Medical Home Model” is one view of the coordinated care model. The Web teleconference will overview this model and the potential role of the pathologist. Where and what are the current pilots and lessons learned? How can a pathologist participate in the pilots? What is CAP’s vision for the pathologist in the coordinated care model?
Speakers: James M. Crawford, MD, PhD, FCAP, and John Scott, vice president, Advocacy
Tuesday, March 9, 9:00-10:00 AM CST
Biorepositories are already beginning to serve as foundations upon which to base molecular test development and validation. In the near future, they will be critical for personalized patient care as diagnostic, prognostic, and therapeutic regimens become customized for the care of the individual patient. What is the role for the practicing pathologist? How steep is the investment to get started? What are the regulations you must adhere to? What are the business models? What types of biorepositories and biospecimens fit your environment? What are the IT aspects in linking the clinical information to the specimen? This is a glimpse into the not-so-distant future in which biorepositories adhering to national standards will become more common, and biospecimen collections will perhaps integrate itself into the standard of care. Sign up to get an introduction into what is involved in running a biorepository, including an overview of financial, logistic, IT, and regulatory challenges.
Speaker: Rajesh C. Dash, MD, FCAP and James A. Robb, MD, FCAP
April 2010: Date/time to be announced on the CAP website
To register for these PHC Web teleconferences, visit the CAP website, select the “Education Programs” on the home page, and then select “Personalized Health Care” in the course catalog. There is no charge for the Web teleconferences. Questions can be directed to email@example.com or 847-832-7000.
Please note that the PHC Web teleconferences will be recorded so that you can listen to sessions at a later time. There is no charge for the programs.
The CAP’s Personalized Health Care Committee focuses on coordination, monitoring, and communication facilitation as it relates to personalized health care and its impact on key activities of the College including government advocacy; patient advocacy; proficiency testing; resources for reporting of pathology results of tests that have personalized health care implications such as risk stratification, therapy selection, etc; and education of pathologists regarding the concept and practice of personalized medicine and clinicals to understand pathology results as they pertain to personalized health care.